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Background: Dual antiplatelet therapy with aspirin and thienopyridine is required after placement of coronary
drug-eluting stents (DES) to prevent thrombotic complications. Current clinical guidelines recommend at least 6 to
12 months of treatment after a DES implantation, but it may be beneficial to apply dual antiplatelet therapy for a
longer duration.
Methods/design: The optimal dual antiplatelet therapy (OPTIDUAL) study aims to compare the benefits and risks
of dual antiplatelet therapy applied for either 12 or 48 months. We will examine the occurrence of major adverse
cardiovascular and cerebrovascular events (MACCE) in patients undergoing percutaneous coronary intervention
with DES for the treatment of coronary lesions. The OPTIDUAL study is an open-label multicenter, randomized,
national trial that will include 1,966 patients treated with DES. All patients will be treated with dual antiplatelet
therapy for 12 months (+/− 3). Then, patients with no MACCE or major bleeding will be randomized to receive
either 36 additional months of clopidogrel plus aspirin or aspirin only. The primary end-point is the combination of
death from all causes, myocardial infarction, stroke and major bleeding. The secondary end points include the
individual components of the primary end-point, stent thrombosis, repeat revascularization of the treated vessel
and minor bleeding.
Discussion: This randomized trial is designed to assess the benefits and safety of 12 versus 48 months of dual
antiplatelet therapy in patients that receive a DES. We aim to determine whether substantial prolongation of
clopidogrel (a thienopyridine) after DES implantation offers an advantage over its discontinuation.
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In the first series of patients receiving a bare metal
stent (BMS), stent thrombosis was already recognized
as a severe complication after implantation owing to its
high mortality. With the introduction of P2Y-receptor
antagonists (that is, ticlopidine, clopidogrel) for platelet
inhibition in combination with acetylsalicylic acid
(ASA), the incidence of stent thrombosis decreased
substantially in stable patients to levels as low as 1%
[1]. Randomized controlled trials have established the
efficacy of clopidogrel therapy following hospitalization
in patients with acute coronary syndrome (ACS) that
were treated either medically or with percutaneous cor-
onary intervention (PCI) [2-4]. The implantation of
drug-eluting stents (DES) has become a standard treat-
ment for the management of patients with coronary ar-
tery disease. The widespread use of DES has significantly
reduced the risk for in-stent restenosis compared to BMS
[5,6]. However, there is some concern that DES might be
associated with high rates of stent thrombosis, particu-
larly beyond the first year after implantation [7]. The
dominant risk factor for the occurrence of late stent
thrombosis is discontinuation of antiplatelet therapy, in-
cluding aspirin and thienopyridines (clopidogrel and
prasugrel). Late stent thrombosis occurs within the first
year after implantation of a DES [8-13]. It remains un-
known whether it might be advantageous to prolong the
12-month antiplatelet thienopyridine (clopidogrel) ther-
apy after DES implantation.
A recent update of the guidelines for PCI from the
American College of Cardiology/American Heart Asso-
ciation/Society of Cardiovascular Angiography and
Interventions stressed that all patients that receive a
DES should be given clopidogrel treatment for at least
12 months in the absence of increased risk of bleeding
[14]. Interestingly, the European Society of Cardiology
guidelines on PCI differ slightly; they recommend
clopidogrel therapy for 6 to 12 months after implant-
ation of a DES, and for 9 to 12 months when a stenting
procedure follows a presentation of an acute coronary
syndrome (ACS) [15].
Early observational studies have suggested that
extended use of clopidogrel in patients with a DES may
be associated with reduced risk of death and myocardial
infarction (MI) [7]. Additional studies have observed a
clustering of adverse events in the initial 90 days after
discontinuation of clopidogrel; this suggested the possi-
bility of a clopidogrel rebound effect [16]. Based on
those results, and also taking into account results from
the Clopidogrel versus Aspirin in Patients at Risk of Is-
chemic Events (CAPRIE) study, some experts have
advocated indefinite clopidogrel therapy [17]. However,
when considering the potential beneficial effects of dual
antiplatelet therapy, it is important to be aware thatextending dual antiplatelet therapy beyond one year may
induce bleeding complications. A meta-analysis of dual
antiplatelet therapy has shown that this combination,
compared to aspirin alone, reduced the risk of death,
reinfarction and stroke by 15 to 34%; however, this bene-
fit occurred at the expense of excess bleeding (odds ratio
1.80, 95% confidence interval 1.40 to 2.30) [18].
Very recently, three trials have been published
suggesting that a shorter duration of dual antiplatelet
therapy after stent implantation may be beneficial
[19-21]. However, to date, it is unknown whether
prolonged dual antiplatelet therapy will decrease major
adverse cardiovascular and cerebrovascular events
(MACCE) that occur more than 12 months after stent
implantation, including very late stent thrombosis. Fur-
thermore, it is uncertain what the optimal duration
would be for long-term dual antiplatelet therapy. There-
fore, given the lack of data from randomized studies, the
aim of the OPTIDUAL study is to assess the benefits
and safety of 12 versus 48 months of dual antiplatelet
therapy in patients that receive a DES.
Methods/design
The primary objective of the OPTIDUAL study (URL:
ClinicalTrials.gov, number NCT00822536; approved by
the ethical committee, number CPP 34–2008) is to com-
pare the efficacy of 12 versus 48 months of dual
antiplatelet therapy after DES implantation. We will test
the hypothesis that 48 months is superior to 12 months
of dual antiplatelet therapy.
Population
The study population will consist of 1,966 patients that
have been taking dual antiplatelet therapy for 12 months
(+/− 3) after DES implantation. All patients will provide
written informed consent to participate. At the beginning
of the OPTIDUAL study, the patients will be randomized
to either discontinue clopidogrel (12 months total) or
to receive clopidogrel for an additional 36 months
(48 months total). Inclusion and exclusion criteria are
detailed in Table 1. No exclusion criterion is based on
the type of DES implanted. Patients will be randomized
without regard to the clinical status at presentation,
including ACS, angina and silent myocardial ische-
mia. All enrolled subjects will have been treated with
an approved DES and will have received 12 months
(+/− 3) of aspirin plus thienopyridine. Doses of aspirin
and clopidogrel will be based on the local standard of
practice. Subjects may be enrolled into the study
starting from immediately after the DES implantation,
up to 12 months (+/− 3) after the DES, provided that
they are on dual antiplatelet therapy. Dual antiplatelet
therapy must include at least six months of aspirin plus
clopidogrel (three months of initial prasugrel is permitted).
Table 1 Inclusion and exclusion criteria
Inclusion criteria: 1. Patients with DES implanted, then treated with clopidogrel plus aspirin for 12 months
2. Informed, written consent from the patient
Exclusion criteria: 1. Age <18 years
2. Oral anticoagulation therapy
3. Drug-eluting stent in an unprotected left main coronary artery
4. Contemporaneous enrollment in a different clinical trial
5. Malignancies or other comorbid conditions with a life expectancy <2 years
6. Known allergy or intolerance to the study medications: aspirin and/or clopidogrel
7. Other revascularization with a DES within nine months prior to this study
8. Other revascularization with a BMS within four weeks prior to this study
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study sites in France.
Study design
Inclusion/exclusion criteria
The major exclusion criteria include 1) taking an oral
anticoagulant therapy and 2) DES implantation in an un-
protected left main coronary artery. BMS implantation
in the same procedure is allowed. The complete list of
inclusion and exclusion criteria is provided in Table 1.
Malignancies and other comorbid conditions with a life
expectancy <2 years are exclusion criteria screened by
the principal investigator of each site. Patients with DES
treated for 12 months (+/− 3) with aspirin and
clopidogrel and who are event-free since the stent im-
plantation (from myocardial infarction (MI), stent
thrombosis, acute coronary syndrome, stroke, repeat
coronary revascularization with a DES in the nine previ-
ous months or with a BMS in the last four weeks, mod-
erate or major bleeding) are eligible for randomization.
Randomization
The patients are randomized (1:1) to receive either as-
pirin alone or a continuation of clopidogrel plus aspirin
for an additional 36 months. Randomization is stratified
by centers. A centralized telephone randomization will
be used with an interactive voice response system that
operates 24 h per day, seven days per week. This system
will provide the investigator with a subject number and
treatment arm.
Dosing regimens
After the index procedure, all subjects will take a daily dose
of open-label clopidogrel and aspirin for 9 to 15 months
after the index procedure. To minimize bleeding risk,
the study will recommend that the aspirin dose should
be the lowest acceptable dose, based on the physician’s
discretion (75 to 160 mg) [22]. The recommended
clopidogrel dosing will be a loading dose between 300
and 600 mg, and a maintenance dose of 75 mg daily tobe continued for the duration of the treatment. Compli-
ance is checked by a patient’s diary where the daily dose of
each drug is reported. According to the results of
CURENT-OASIS-7, clopidogrel dosing could be 150 mg
per day for one week after the stent implantation in the
setting of ACS [23]. Prasugrel could be administered after
a PCI, but for no longer than three months. Patients that
are not switched from prasugrel to clopidogrel at three
months will not be randomized.
Follow-up
All randomized patients will be followed up for 36 months
after randomization. Thus, patients randomized in
the clopidogrel group will receive dual antiplatelet ther-
apy (clopidogrel plus aspirin) for a total of four years
(+/− three months). The other patients will receive as-
pirin alone (75 to 160 mg daily). Demographic, clinical
and procedural information will be captured at the time
of enrollment. In addition, we will record subsequent
clinical end-points, serious adverse events and con-
comitant medications. Time of randomization that is
the time when the studied strategy is beginning (that is,
stopped or sustained dual therapy) will be considered
as the time 0 for study endpoints. Subjects will be
contacted at 6, 12, 18, 24, 30 and 36 months after the
randomization; that is, up to 48 months after the DES
implantation. All end points and events that occur after
randomization will be adjudicated by an independent
Clinical Events committee, blinded to the assignment
strategy. The committee will comprise physicians that
are provided with all the data from medical records ne-
cessary to perform optimal adjudication.
Study end-points
The primary end-point of the study is the incidence of a
composite end-point, including all-cause mortality, MI,
stroke and major bleeding events. The MIs will be classi-
fied and adjudicated according to the Academic Research
Consortium (ARC) definition [24]. Major bleeding events
will be classified as fatal bleeding, intra-cranial bleeding
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need for transfusion of at least two units of packed red
blood cells, reductions in hemoglobin greater than 3 g/dl,
intra-ocular bleeding that leads to visual loss or bleeding
that requires surgery.
The secondary end-points of the study include the indi-
vidual components of the primary composite end-point,
stent thrombosis according to the ARC definition, repeat
vessel revascularization and minor bleeding events.
Statistical considerations
Sample size
A sample size of 983 patients per group was calculated
to provide an 80% power to demonstrate a difference be-
tween the two groups by survival analysis based on a
Cox model. We assumed that the primary composite
endpoint within three years post-randomization would
be equal to 7% in one group vs. 4% in the other with an
accrual period of 36 months. We also assumed a 5%
two-sided significance level [25].
Study termination rules
An interim analysis will be made after 50% of the
expected events have occurred. The study can be
stopped to evaluate efficacy based on the conservative
criterion of Peto (P <0.001). Based on a Bayesian calcula-
tion of conditional power (with Addplan software GmbH
Koln Germany), the sample size can be reassessed and,
when deemed futile, the study can be terminated [26].
Statistical analysis
All analyses will include the intention-to-treat popula-
tion (all patients randomly assigned to treatment groups
and analyzed as randomized, that is, patients crossing-
over from one strategy to another will be analyzed in
function of their group of randomization). Patients who
drop-out will be censored at the time of the last available
information.
The primary and secondary endpoints that are related
to the time to an event will be analyzed with a survival
analysis based on a Cox model. Alternative statistical
models will be used when hypotheses regarding risks
cannot be suitably analyzed with the Cox model. Other
secondary endpoints will be analyzed with the χ2 or
Fisher’s exact test for frequent comparisons. Two-sided
significance level is fixed at 5%. All tests will be
performed with SAS version 9.3 (SAS Institute Inc.,
Cary, NorthCarolina, USA).
Study management
The OPTIDUAL study is planned to be a multicenter
open-label trial, conducted in France, and sponsored by
the Assistance Publique des Hôpitaux de Paris (Paris,
France). Funding has been obtained from the AssistancePublique des Hôpitaux de Paris. An executive committee
composed of experienced clinical investigators will pro-
vide trial leadership. A clinical events committee,
blinded to the assignment strategy, will adjudicate all
clinical events and a Data and Safety Monitoring Board
(DSMB) is working. The committee will comprise
physicians that are provided with all the data from med-
ical records necessary to perform optimal adjudication.
Discussion
Several pivotal clinical trials have shown that, compared
to a BMS, the DES is associated with significant
reductions in the risk of restenosis and the need for
target-lesion revascularization [5,6]. Early discontinu-
ation of dual antiplatelet therapy has been identified as a
risk factor for late stent thrombosis in patients with DES
[9]. Furthermore, it was suggested that some late clinical
events that occur later than one year after DES implant-
ation may be due to delayed arterial healing after the im-
plantation of DES. Therefore, current guidelines
recommend aspirin and clopidogrel at a dose of 75 mg
daily for at least 12 months after DES implantation for
patients that are not at high risk for bleeding. However,
it remains unknown what the optimal duration might be
for dual antiplatelet therapy and whether the risk-benefit
ratio could be improved with long-term dual antiplatelet
therapy for patients that receive DES. Due to the large
number of DES implantations in the world each year,
the optimization of dual antiplatelet therapy is important
for both patient recovery and economic efficiency. The
first randomized study on this issue was performed in
Korea [19]. They analyzed combined data from two
multicenter trials, the REAL-LATE and the ZEST-LATE
trials. That study found that no significant benefit was
associated with continuing clopidogrel plus aspirin be-
yond the 12-month treatment following DES implant-
ation. They saw no reductions in the incidence of
myocardial infarction or death from cardiac causes.
Moreover, the rates of composite outcomes (MI,
stroke, death) were higher with clopidogrel plus aspirin
than with aspirin alone, although the difference was
not significant. Recently, two additional studies
investigated the effects of long-term dual antiplatelet
therapy. The EXCELLENT study, by Gwon et al.,
showed that, at 12 months after DES implantation,
patients treated with 12-month and 6-month dual
antiplatelet therapy showed similar risks for target ves-
sel failure, defined as the composite of cardiac death,
MI and ischemia-driven target vessel revascularization
[20]. However, the non-inferiority margin was wide, and
the study was underpowered for death and MI. In the
other study, by Valgimigli et al., 24 months of clopidogrel
therapy in patients with DES or BMS was not significantly
more effective than a 6-month clopidogrel regimen for
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brovascular accident [21]. In that study, two years of
clopidogrel therapy resulted in a significant increase in
bleeding episodes. Although those studies were interesting,
and they suggested the possibility that a shorter dual
antiplatelet therapy might be sufficient after DES implant-
ation, they did not rule out the possibility that prolonging
the clopidogrel plus aspirin treatment might result in a re-
duction of MACCE.
Given the importance of this subject, it is not surpris-
ing that a few clinical trials are currently ongoing to in-
vestigate optimal treatment times. The dual antiplatelet
therapy (DAPT) study aims to compare the benefits and
risks of 12 versus 30 months of dual antiplatelet therapy
in patients undergoing PCI, and it has the largest num-
ber of subjects [27]. Over 20,000 subjects will be en-
rolled at approximately 220 international clinical study
sites. Most of the patients (>15,000) will receive a DES.
Interestingly, in that prolonged combined antiplatelet
therapy, patients will receive either clopidogrel or
prasugrel, a new thienopyridine that recently appeared
on the market. Another interesting ongoing trial aims to
assess whether discontinuation of clopidogrel plus as-
pirin at six months after DES implantation would be
non-inferior to a routine, one-year treatment [28].
Conclusion
Our trial will conduct a substantially prolonged treat-
ment of clopidogrel plus aspirin, for up to four years
after DES implantation. We aim to determine whether
long-term treatment would be superior to discontinu-
ation at one year.
Trial status
This study is currently recruiting patients.
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